Maybe the pathogenesis gives us a clue on how to target things? Possibly the treatments which take down synovitis might not always help with nodules Christopher Edwards #EULAR2025 @RheumNow https://t.co/T6QHCS8709

• https://x.com/drdavidliew/status/1933491474056032437/photo/1
• https://x.com/drdavidliew/status/1933491474056032437/photo/1
• https://x.com/drdavidliew/status/1933491474056032437/photo/1

#EULAR2025 Abstr#POS0320 Data from TULIP+LTE compared to Lupus Toronto Cohort as Control showed Anifrolumab reduced organ damage progression up to 4 years vs real-world SOC in #SLE. Effect continued to 10yrs using novel extrapolate analysis @RheumNow https://t.co/bkjZCZ8xGr

• https://x.com/Yuz6Yusof/status/1933491657250410888/photo/1

What is new in SpA? ‼️nomenclature change: 🚫AS≠ Ankylosing spondylitis ✅AS= Axial spondyloarthritis -Helena Marzo-Ortega at #EULAR2025 @RheumNow

Delay hurts. Dx delay in axial SpA costs UK £3.1 billion annually. Avg time to dx = 8.5 yrs Avg dx cost = £187k/person Fixing delay could save £167k/person. Early Dx isn’t just better care—it’s economic policy. #EULAR2025 @RheumNow #AxialSpA #RMD https://t.co/eYEQ2rp94m

• https://x.com/JihaRheum/status/1933492091457331458/photo/1

@RheumNow So rheumatoid nodule treatment might target some of that pathophysiology. Rituximab, abatacept, or JAKi? And while surgery often isn’t great (plus they often grow back), definitely an option for some. Christopher Edwards #EULAR2025 @RheumNow https://t.co/sFWnQN8uC4

• https://x.com/drdavidliew/status/1933492490843402509/photo/1
• https://x.com/drdavidliew/status/1933492490843402509/photo/1
• https://x.com/drdavidliew/status/1933492490843402509/photo/1

#Psoriatic_Arthritis #Preclinical #Early ❓️ Does joint swelling occur in the same anatomical locations affected in the subclinical phase? 🅰️ Yes, in 68% 🅰️ Especially if positive ultrasound #EULAR2025 @RheumNow OP0179 by Ivan Giivannini et al. https://t.co/rKfreQyJeG

• https://x.com/Nellziade/status/1933493091861680355/photo/1

#EULAR2025 Abstr#POS0321 In addition to complete renal response attainment as you already know, exploratory analysis from REGENCY showed Obinutuzumab+SOC reduced #lupus nephritis flare and unfavourable kidney outcomes vs PBO+SOC. Longterm kidney survival protection @RheumNow https://t.co/vRFb94TXaQ

• https://x.com/Yuz6Yusof/status/1933494060087492672/photo/1

Rheumatoid vasculitis: what to look for and how to find it #EULAR2025 @AshimaMakol @RheumNow https://t.co/ZCUXgOr1dH

• https://x.com/drdavidliew/status/1933494879168184699/photo/1

Acute Dactylitis in #Psoriatic_Arthritis 🔹️1216 patients Canada 🇨🇦 🔹️52% had at least one episode of acute dactylitis in a median 12 years 🔹️Positive association with HLA-B27 and HLA-B27/C02 🔹️No association with HLA-B51 #EULAR2025 @RheumNow OP0180 by Kharouf et al. https://t.co/oNNMBcvVb4

• https://x.com/Nellziade/status/1933495415330205828/photo/1

How to treat rheumatoid vasculitis #EULAR2025 @AshimaMakol @RheumNow https://t.co/A8oqPd6bJx

• https://x.com/drdavidliew/status/1933497359805427734/photo/1

#EULAR2025 Abstr#OP0324 Cohort study of #lupus nephritis in Greece showed Earlier GC Discontinuation (D/C) & flare protection post-D/C is associated with renal response, low disease activity & HCQ use at GC D/C. Membranous LN & recent diagnosis were assoc w early GC D/C @RheumNow https://t.co/agFgyG5eaS

• https://x.com/Yuz6Yusof/status/1933498445408391219/photo/1

Should we still be worried about lymphoma developing in RA patients? Incidence has plummeted with modern therapy, although still a small risk. TNFi and other bDMARDs don’t seem to confer any real risk. So what should our approach be? Karin Hellgren #EULAR2025 @RheumNow https://t.co/9ZodpojSaz

• https://x.com/drdavidliew/status/1933501423742038489/photo/1

About #Multidisciplinarity ... Dr Ihsane Hmamouchi talking about Multidisciplinary Approach to Migrant #Rheumatology Care #quotes #EULAR2025 #Invitedspeaker #outofthebox @RheumNow @epirheum https://t.co/RG6xpHejv9

• https://x.com/Nellziade/status/1933503623708704963/photo/1

#EULAR2025 Abstr#POS0991 RCT showed Adjuvanted Herpes Zoster vaccination appeared safe in #SLE upto 1 year. However, humoral and cellular responses declined over time. Longer follow up needed to ascertain frequency of vaccine to be repeated @RheumNow https://t.co/FcUi1OfBLu

• https://x.com/Yuz6Yusof/status/1933505343918649567/photo/1

What kills in GCA? Greek national prospective cohort, small numbers and no doubt some channeling bias, but: Steroids (absence of DMARD use) is more of a factor than CV disease in GCA mortality. With new options, all GCA pts should be on something #EULAR2025 POS0960 @RheumNow https://t.co/Wmvf6tEvaF

• https://x.com/drdavidliew/status/1933511888719274282/photo/1